LIBERTYVILLE TOWNSHIP - Abbott Laboratories sued Teva Pharmaceutical Industries Ltd., the world's largest generic-drug maker, to prevent it from marketing copies of the Zemplar kidney-disease treatment. Abbott and patent partner the Wisconsin Alumni Research Foundation contend Israel's Teva plans to begin selling a generic version of the injectable medicine, known chemically as paricalcitol, before three U.S. patents expire in 2018. Teva "actively reviews pharmaceutical patents and seeks opportunities to challenge those patents," Abbott lawyers said in a complaint filed yesterday in federal court in Wilmington, Del. Teva told the U.S. Food and Drug Administration the patents "are invalid, unenforceable, or will not be infringed," according to the complaint.